[go: up one dir, main page]

MX2014005075A - Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. - Google Patents

Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.

Info

Publication number
MX2014005075A
MX2014005075A MX2014005075A MX2014005075A MX2014005075A MX 2014005075 A MX2014005075 A MX 2014005075A MX 2014005075 A MX2014005075 A MX 2014005075A MX 2014005075 A MX2014005075 A MX 2014005075A MX 2014005075 A MX2014005075 A MX 2014005075A
Authority
MX
Mexico
Prior art keywords
pyrazole
benzo
dichloro
imidazo
meglumine salt
Prior art date
Application number
MX2014005075A
Other languages
English (en)
Other versions
MX344109B (es
Inventor
Michele C Rizzolio
Kia Sepassi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2014005075A publication Critical patent/MX2014005075A/es
Publication of MX344109B publication Critical patent/MX344109B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe la sal de meglumina del ácido 1-(5,6-dicloro-1H- benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico (compuesto (1)) y formulaciones farmacéuticamente aceptables de ésta; dichos compuestos se pueden usar en composiciones farmacéuticas y métodos para el tratamiento de enfermedades, trastornos y condiciones mediadas por la actividad de prolil hidroxilasas.(ver Fórmula).
MX2014005075A 2011-10-25 2012-10-25 Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico. MX344109B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551395P 2011-10-25 2011-10-25
PCT/US2012/061847 WO2013063221A1 (en) 2011-10-25 2012-10-25 Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid

Publications (2)

Publication Number Publication Date
MX2014005075A true MX2014005075A (es) 2014-08-08
MX344109B MX344109B (es) 2016-12-05

Family

ID=47116519

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015990A MX368157B (es) 2011-10-25 2012-10-25 Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
MX2014005075A MX344109B (es) 2011-10-25 2012-10-25 Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016015990A MX368157B (es) 2011-10-25 2012-10-25 Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.

Country Status (14)

Country Link
US (4) US9273034B2 (es)
EP (3) EP2776023B1 (es)
JP (2) JP6122862B2 (es)
KR (1) KR102087020B1 (es)
CN (2) CN104053439B (es)
AU (2) AU2012328763A1 (es)
BR (1) BR112014009910B1 (es)
CA (1) CA2853455C (es)
CY (1) CY1123426T1 (es)
ES (3) ES2689481T3 (es)
HU (1) HUE052128T2 (es)
IN (1) IN2014DN03155A (es)
MX (2) MX368157B (es)
WO (1) WO2013063221A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20141038T2 (hr) 2008-04-28 2015-07-03 Janssen Pharmaceutica N.V. Benzoimidazoli kao inhibitori prolil hidroksilaze
CN115403531A (zh) 2011-09-14 2022-11-29 润新生物公司 作为激酶抑制剂的化学实体、组合物及方法
MX368157B (es) 2011-10-25 2019-09-20 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
EP2916838B1 (en) 2012-11-12 2019-03-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN104610153B (zh) * 2015-01-19 2017-02-22 沈阳中海生物技术开发有限公司 奥扎格雷葡甲胺盐及其组合物、制备方法和用途
AU2019319448B2 (en) 2018-08-07 2022-06-02 Metagone Biotech Inc. Ammonium salts of 3-(3,5-dibromo-4-hydroxybenzyliden)-5-indo-1,3-dihydroindol-2-one and uses thereof
BR112022010388A2 (pt) 2019-11-28 2022-10-25 Nihon Nohyaku Co Ltd Composto de benzimidazol ou sal deste, agente inseticida e acaricida agrícola e hortícola que contém o referido composto e método para sua utilização
US20230218592A1 (en) 2020-04-20 2023-07-13 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
WO2025049599A1 (en) 2023-08-29 2025-03-06 President And Fellows Of Harvard College Methods for treating muscle-related disorders by modulating prolyl hydroxylase 3

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
EP0266940B1 (en) 1986-10-22 1992-12-16 Schering Corporation Use of recombinant human alpha interferon for the manufacture of a medicament for the treatment of aids virus
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
US5258362A (en) 1991-06-11 1993-11-02 Abbott Laboratories Renin inhibiting compounds
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
JP3314938B2 (ja) 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
ZA981936B (en) 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
SK12342000A3 (sk) 1998-02-27 2001-03-12 Pfizer Products Inc. Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie
EP1502539B1 (en) 1999-11-22 2011-04-20 Mallinckrodt Inc. Pulse oximeter sensor with widened strip
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
CN102718708A (zh) 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
SI1660492T1 (sl) 2003-07-28 2009-02-28 Janssen Pharmaceutica Nv Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H
BRPI0418212A (pt) 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
RU2457204C2 (ru) 2006-01-27 2012-07-27 Файброджен, Инк. Цианоизохинолиновые соединения (варианты), фармацевтическая композиция на их основе, способ ингибирования активности гидроксилазы гипоксия-индуцибельного фактора (hif) и способ лечения и/или профилактики состояния, связанного с hif, и/или состояния, связанного с эритропоэтином, и/или анемии
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
JP2009537558A (ja) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
DK3026044T3 (en) 2006-06-26 2019-02-18 Akebia Therapeutics Inc PROLYL HYDROXYLASE INHIBITORS AND METHODS FOR USE
WO2008033739A2 (en) 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
US8278337B2 (en) 2006-12-20 2012-10-02 Merck Sharp & Dohme Substituted pyridines that are JNK inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
CN101663037A (zh) 2007-04-18 2010-03-03 默克公司 新的1,8-二氮杂萘化合物
CA2683956C (en) 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
JP2010536807A (ja) * 2007-08-22 2010-12-02 ４エスツェー アクチェンゲゼルシャフト キネシンスピンドルタンパク質（ｅｇ５）の阻害剤としてのインドロピリジン
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
DE102007049157A1 (de) 2007-10-13 2009-04-16 Bayer Healthcare Ag Substituierte Dihydrotriazolone und ihre Verwendung
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
CN101951775A (zh) 2008-02-25 2011-01-19 默沙东公司 四氢噻吩并吡啶
EP2257171B1 (en) 2008-02-25 2016-02-10 Merck Sharp & Dohme Corp. Tetrahydro-1h-pyrrolo-fused pyridones
US8471024B2 (en) 2008-02-25 2013-06-25 Merck Sharp & Dohme, Corp. Tetrahydrofuropyridones
AU2009225869B2 (en) 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
HRP20141038T2 (hr) * 2008-04-28 2015-07-03 Janssen Pharmaceutica N.V. Benzoimidazoli kao inhibitori prolil hidroksilaze
CN102388037B (zh) 2009-02-10 2014-12-03 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的喹唑啉酮
AU2011289230B2 (en) 2010-08-13 2014-09-04 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
MX368157B (es) 2011-10-25 2019-09-20 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.

Also Published As

Publication number Publication date
AU2017204598A1 (en) 2017-07-27
CN104053439B (zh) 2016-08-24
BR112014009910A2 (pt) 2017-04-25
JP2014530915A (ja) 2014-11-20
MX344109B (es) 2016-12-05
MX368157B (es) 2019-09-20
WO2013063221A1 (en) 2013-05-02
EP3461820B1 (en) 2020-07-29
EP2776023A1 (en) 2014-09-17
US20180201605A1 (en) 2018-07-19
AU2012328763A1 (en) 2014-05-01
CN106038556A (zh) 2016-10-26
US20190152955A1 (en) 2019-05-23
AU2017204598B2 (en) 2019-03-28
EP2776023B1 (en) 2016-03-09
US9273034B2 (en) 2016-03-01
ES2574262T3 (es) 2016-06-16
CY1123426T1 (el) 2021-12-31
KR102087020B1 (ko) 2020-03-11
HUE052128T2 (hu) 2021-04-28
EP3091009A1 (en) 2016-11-09
BR112014009910B1 (pt) 2020-06-30
EP3461820A1 (en) 2019-04-03
US10807969B2 (en) 2020-10-20
US20160340338A1 (en) 2016-11-24
JP2017141270A (ja) 2017-08-17
EP3091009B1 (en) 2018-08-29
ES2689481T3 (es) 2018-11-14
CN104053439A (zh) 2014-09-17
KR20140094547A (ko) 2014-07-30
CA2853455A1 (en) 2013-05-02
HK1202237A1 (zh) 2015-09-25
CA2853455C (en) 2019-12-03
ES2818977T3 (es) 2021-04-14
IN2014DN03155A (es) 2015-05-22
US9708298B2 (en) 2017-07-18
JP6122862B2 (ja) 2017-04-26
NZ624022A (en) 2015-05-29
US20140329873A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
MX344109B (es) Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010093727A8 (en) Quinazolinones as prolyl hydroxylase inhibitors
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
WO2009106980A3 (en) Indazole derivatives
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
MX380928B (es) Inhibidores de kras g12c.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MY162936A (en) Macrocycles as factor xia inhibitors
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
UA99787C2 (en) Lactams as beta secretase inhibitors
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
HK1202448A1 (en) Topical formulation for administering a compound
MX2010009462A (es) Derivados de indazol.
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
IN2013DN02555A (es)
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).

Legal Events

Date Code Title Description
FG Grant or registration